SCOTS stem cell storage company Pharmacells is poised to acquire the assets of Edinburgh-based biotech firm Immunosolv, in a deal bosses believe will propel it to "world-leader" status in the supply of stem cells for research.
Pharmacells, which is based in Newhouse, North Lanarkshire, said it was close to completing a successful takeover of the assets of Immunosolv, which went into liquidation in mid-March.
The deal will give Pharmacells the rights to potentially lucrative intellectual property, including research and product patents, as well as gaining access to valuable hi-tech equipment – some of it designed and trademarked by Immunosolv.
It is understood that Pharmacells also plans to retain one Immunosolv employee, described as a "highly-qualified" specialist researcher.
The acquisition is being undertaken in partnership with Aberdeen-based Grampian Biopartners.
Among the prized assets in the takeover is access to "Dead-Cert", a method of cell extraction developed and patented by Immunosolv which will play a crucial role in improving Pharmacell's productivity. The Lanarkshire firm has already patented its own technique for isolating, harvesting and storing a newly discovered type of blood-derived adult stem cell, which can be used to generate lines of any other cell type in the body, from brain cells to liver cells.
The technology has already been used to create a private stem cell bank where members of the public can pay around £3000 to store their blood-borne stem cells for potential, personalised medical therapies in future, as well as providing an ethically sound supply of stem cells to researchers.
However, being able to use Immunosolv's Dead-Cert method, which weeds out dead and damaged cells, will mean Pharmacells can increase its average harvest of healthy cells from around 60% to at least 80%.
Atholl Haas, chief executive of Pharmacells, said he looked forward to being able to getting access to a raft of high-quality products, research and equipment and apply a stronger business model to their use.
He said: "Immunosolv has been around since the mid-1990s, and it had around £1 million of venture capital funding on its books at the time it went into liquidation, so we will get access to that as well. It had great products but a bad business sense. It was driven by academics and academic research grants, which is great for science but not so great for a viable biotech company.
"Immunosolv will mean we have the best basis for stem cell therapy on the planet: the most cells, the youngest – bar embryonic – and the highest purity. We can supply a better product to researchers to further their work, and be a world leader."
The acquisition comes as Pharmacells is expanding its global reach, with its blood stem cell banking service now available in Hong Kong, the United Arab Emirates, Pakistan, Spain, and Portugal, though all samples are flown back to their hub in Lanakshire.
The firm hopes to expand the service to 20 countries by the end of the year.
This article has been updated on the basis of new information.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article